» Articles » PMID: 12846969

Description of Parkinson's Disease As a Clinical Syndrome

Overview
Specialty Science
Date 2003 Jul 9
PMID 12846969
Citations 317
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinsonism is a clinical syndrome comprising combinations of motor problems-namely, bradykinesia, resting tremor, rigidity, flexed posture, "freezing," and loss of postural reflexes. Parkinson's disease (PD) is the major cause of parkinsonism. PD is a slowly progressive parkinsonian syndrome that begins insidiously and usually affects one side of the body before spreading to involve the other side. Pathology shows loss of neuromelanin-containing monoamine neurons, particularly dopamine (DA) neurons in the substantia nigra pars compacta. A pathologic hallmark is the presence of cytoplasmic eosinophilic inclusions (Lewy bodies) in monoamine neurons. The loss of DA content in the nigrostriatal neurons accounts for many of the motor symptoms, which can be ameliorated by DA replacement therapy-that is, levodopa. Most cases are sporadic, of unknown etiology; but rare cases of monogenic mutations (10 genes at present count) show that there are multiple causes for the neuronal degeneration. The pathogenesis of PD remains unknown. Clinical fluctuations and dyskinesias are frequent complications of levodopa therapy; these, as well as some motor features of PD, improve by resetting the abnormal brain physiology towards normal by surgical therapy. Nonmotor symptoms (depression, lack of motivation, passivity, and dementia) are common. As the disease progresses, even motor symptoms become intractable to therapy. No proven means of slowing progression have yet been found.

Citing Articles

Assessment of gastrointestinal function and enteric nervous system changes over time in the A53T mouse model of Parkinson's disease.

Han M, Di Natale M, Lei E, Furness J, Finkelstein D, Hao M Acta Neuropathol Commun. 2025; 13(1):58.

PMID: 40075409 PMC: 11899089. DOI: 10.1186/s40478-025-01956-7.


1,4-dihydroxy-2-naphthoic acid prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced motor function deficits.

Madison C, Debler R, Gallegos P, Hillbrick L, Chapkin R, Safe S Behav Pharmacol. 2024; 36(1):40-46.

PMID: 39660867 PMC: 11781791. DOI: 10.1097/FBP.0000000000000806.


New application of ombuoside in protecting auditory cells from cisplatin-induced ototoxicity via the apoptosis pathway.

Wu X, Peng X, Zhang Y, Peng W, Lu X, Deng T Heliyon. 2024; 10(20):e39166.

PMID: 39640804 PMC: 11620119. DOI: 10.1016/j.heliyon.2024.e39166.


The Influence of Dopaminergic Medication on Regularity and Determinism of Gait and Balance in Parkinson's Disease: A Pilot Analysis.

Workman C, Thrasher T J Clin Med. 2024; 13(21).

PMID: 39518623 PMC: 11546099. DOI: 10.3390/jcm13216485.


Striatal Cholinergic Interneurons Control Physical Nicotine Withdrawal via Muscarinic Receptor Signaling.

Kim B, Kim H, Woo J, Lee H, Kim T, Min H Adv Sci (Weinh). 2024; 11(47):e2402274.

PMID: 39491887 PMC: 11653618. DOI: 10.1002/advs.202402274.